Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Elk River Wealth Management LLC

Elk River Wealth Management LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,762 shares of the medical research company’s stock after purchasing an additional 71 shares during the quarter. Thermo Fisher Scientific accounts for about 1.1% of Elk River Wealth Management LLC’s holdings, making the stock its 29th biggest holding. Elk River Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $5,716,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in TMO. Vanguard Group Inc. raised its holdings in Thermo Fisher Scientific by 0.6% during the third quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after purchasing an additional 180,618 shares in the last quarter. State Street Corp raised its holdings in Thermo Fisher Scientific by 0.3% during the second quarter. State Street Corp now owns 16,116,956 shares of the medical research company’s stock worth $8,414,693,000 after purchasing an additional 55,458 shares in the last quarter. Morgan Stanley raised its holdings in Thermo Fisher Scientific by 0.4% during the third quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock worth $6,285,838,000 after purchasing an additional 50,736 shares in the last quarter. Moneta Group Investment Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 104,536.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after acquiring an additional 8,347,260 shares during the period. Finally, Providence Capital Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 61,754.7% in the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock valued at $10,136,000 after acquiring an additional 5,832,730 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price on the stock. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Royal Bank of Canada boosted their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Finally, Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 target price on the stock. Five analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $599.00.

Thermo Fisher Scientific Stock Up 1.3 %

Shares of TMO traded up $7.15 during mid-day trading on Wednesday, reaching $575.97. 886,585 shares of the stock traded hands, compared to its average volume of 1,616,213. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The firm has a market cap of $219.62 billion, a price-to-earnings ratio of 36.84, a P/E/G ratio of 2.41 and a beta of 0.80. The stock has a fifty day simple moving average of $563.78 and a 200 day simple moving average of $519.45.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same quarter in the previous year, the company posted $5.40 earnings per share. The firm’s revenue was down 4.9% on a year-over-year basis. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be given a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Insider Activity at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Debora L. Spar sold 164 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 over the last ninety days. 0.32% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.